

The logo for Seeking Alpha, with the text 'Seeking Alpha' in white and a Greek letter alpha (α) in orange, all on a dark red background.

Acorda Therapeutics, Inc. Q2 2008 Earnings Call Transcript

Question-and-Answer Session

Operator

(Operator instructions) Your first question comes from the line of Joel Sendek with Lazard Capital Markets. Please proceed.

Joel Sendek – Lazard Capital Markets

Hi, thanks. I have a question about what you put in the press release about the extension studies. And in particular, can you let us know if you have the data, what percentage of those on the extension studies are the Walk responders?

Ron Cohen

We don't have that specifically, Joel, although I can tell you that the substantial majority of the people in the extension studies really by definition are not the people who are the Fampridine Timed Walk responders in the double-blind studies. Over 90% of the people in the double-blind studies, which includes the 201, the 202, the 203, 204 studies. Over 90% of those people wound up going into the extension studies. And if you just look, you'll find that the great majority of the people in those studies were either placebo patients or Fampridine Walking non-responders. So it's a mixture of people in the extension studies.

Joel Sendek – Lazard Capital Markets

And then – okay. And then do you know why they go off study?

Ron Cohen

It's a mixture of reasons. It could be perceived lack of efficacy, it could be adverse events, and it could be other, which is a broad category. For example, people move and they go to – they just move to another state. They are no longer near the center, various sorts of administrative issues.

Joel Sendek – Lazard Capital Markets

Okay. All right. Thanks a lot.

Ron Cohen

Sure.

Operator

Your next question comes from the line of Geoff Meacham with JPMorgan. Please proceed.

Matt Roden – JPMorgan

Hi, this is Matt in for Geoff. Can you hear me?

Ron Cohen

Yes. Hi, Matt.

Matt Roden – JPMorgan

Hi. So, I also have a question on the long-term extensions here. Firstly, other than gaining the benefit of Fampridine in mobility, is there any other incentive for staying on study? And then, secondly, is there any update on the safety from the long-term extensions?

Ron Cohen

So, to your first question, the stipulation in the extension study is that patients may stay in the study unless there are adverse events that are mitigating where the physician and/or the patient feel that they can't tolerate it and need to come off, or there is a lack of efficacy. So if they feel – if the physician and the patient feel that they are continuing to benefit and there are no mitigating adverse events, they are permitted to stay on the study. Does that answer your first part of your question, Matt?

Copyright © 2008 CNET Networks, Inc. All Rights Reserved.